EBM Technologies Incorporated (TPEX:8409)
18.25
+0.10 (0.55%)
Sep 8, 2026, 1:14 PM CST
EBM Technologies Revenue
EBM Technologies had revenue of 35.72M TWD in the quarter ending June 30, 2026, with 6.78% growth. This brings the company's revenue in the last twelve months to 283.73M, up 0.26% year-over-year. In the year 2025, EBM Technologies had annual revenue of 253.11M, down -9.91%.
Revenue (ttm)
283.73M
Revenue Growth
+0.26%
P/S Ratio
2.05
Revenue / Employee
n/a
Employees
n/a
Market Cap
580.80M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 253.11M | -27.85M | -9.91% |
| Dec 31, 2024 | 280.95M | 74.81M | 36.29% |
| Dec 31, 2023 | 206.15M | -177.74M | -46.30% |
| Dec 31, 2022 | 383.88M | 188.95M | 96.93% |
| Dec 31, 2021 | 194.93M | -20.40M | -9.47% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| PharmaEssentia | 20.75B |
| Taiwan Advance Bio-Pharmaceutical | 348.54M |
| General Biologicals | 260.23M |
| Bioray Biotech | 207.17M |
| Vectorite Biomedical | 54.81M |
| Caliway Biopharmaceuticals | 29.39M |
| Pell Bio-Med Technology | 28.93M |
| SynCore Biotechnology Co.,Ltd | 26.24M |